Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference
CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at Cantor Fitzgerald’s Global Healthcare 2023 Investor Conference, which will be held on September 26-28, 2023, at the Intercontinental Barclay Hotel in New York, NY. Details are as follows:
Cantor Global Healthcare 2023
The webcast may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Connect” tab. Replays will be available on the website following the conclusion of each event.
About Spero Therapeutics
For more information, visit https://sperotherapeutics.com.
Forward Looking Statements
Investor Relations Contact:
Generative AI Expo #TECHSUPERSHOW Networking LIVE Party
Solutions Showcase Session
Keynote Panel: The Continued Rise of AI: Embracing the Known and Unknown to Drive Business Results